News

July 2009

NeuClone signs deal to develop CHO cell lines for the MENA market.   

NeuClone has entered into a supply agreement with a leading pharmaceutical company headquartered in Egypt.  NeuClone will   provide fully documented mammalian cell lines producing biosimilars for the marketing and distribution of these products  in the Middle East and North African regions.   NeuClone’s platform technology provides improvements in the yield and stability of production cell lines enabling the cost effective manufacture of therapeutic proteins. The agreement adds to a list of growing   partnerships NeuClone has with major international  pharmaceutical companies resulting in milestone and royalty payments.

April 2009

NeuClone hires Cell Culture Scientist/Lab Manager

NeuClone has attracted and hired Dr Nadya Shale for the position of Cell Culture Scientist and Lab Manager.  Dr  Shale completed her PhD in the division of Chemical Bioengineering at the Australian Institute for Bioengineering and Nanotechnology (AIBN)/Department of Chemical Engineering, at the University of Queensland.   Dr Shale has worked on the development of inducible gene expression systems for increased recombinant protein production CHO cells as well the application of a genetic approach to manipulate glycosylation events in CHO cells for enhanced biological activity of recombinant proteins.  Dr Shale brings wide relevant research experience to the company and NeuClone benefits greatly from her expertise and passion for the development of new products in the biotech industry.

March 2009

NeuClone completes relocation into its new labs in the National Innovation Centre of the Australian Technology Park.

NeuClone moves into its fully renovated suite of labs and office space ergonomically designed in function of a seamless workflow of genetic engineering and mammalian cell line development.  The suite consists of  clean rooms for tissue culture and bioprocess development, molecular biology and protein analysis as well as office space for up to 10 staff.

July 2008

NeuClone moves to the Australian Technology Park

July, 2008. NeuClone joins ATP Innovations, a vibrant, world-class technology commercialization hub located within the Australian Technology Park (ATP), on the fringe of the Sydney CBD. The new facilities will allow us to  provide quality products and services in cell line development under strictly regulated conditions.  The facility will be compliant with the Principles of GLP of the OECD under the Australian GLP compliance monitoring program recognized by NATA. Quality Systems are designed to meet the requirements of the cGMP Quality System Regulation, the ISO 13485:2003 international standard. 

Jan 2008

NeuClone is proud to have been selected to participate in a Trade Mission to the United Arab Emirates

January 28-31, 2008. The mission to Dubai was sponsored by the NSW Department of State and Regional Development and coincided with the Arab Health 2008 healthcare exhibition and congress in Dubai, UAE. The Middle East is one of the world's fastest growing and most lucrative healthcare markets, worth over US$81 billion.

Jan 2008

NeuClone receives funding under the Commercial Ready Plus scheme

Through AusIndustry, the Commercial Ready Plus supports research and development, proof-of-concept and early-stage commercialisation activities. Commercial Ready Plus offers innovation grants of up to $250,000 for projects of up to 18 months duration.

Nov 2007

NeuClone receives COMET grant funding

COMET (Commercialising Emerging Technologies) is an Australian government initiative offered through AusIndustry COMET is a competitive, merit based program that supports early-growth stage and spin off companies to successfully commercialise their innovations.

July 2007

NeuClone signs deal to develop CHO cell lines for the Latin American market

NeuClone has entered into a supply agreement with a leading pharmaceutical company in Mexico to  provide fully documented mammalian cell lines producing biosimilars for distribution in the Latin American market.